PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26071519-1	2015	OBJECTIVES: Spurred by the latest EUCAST and CLSI recommendation to adjust antibiotic therapy on the basis of MICs instead of resistance mechanisms, we aimed to investigate the ability of CTX-M-1 and CTX-M-14 to achieve ceftazidime resistance under selective conditions.	Ceftazidime	220-231	CTX-M-1	Escherichia coli	188-208	
15504890-1	2004	A strain of Escherichia coli containing TEM-1 and CTX-M-1 was tested in an in vitro pharmacokinetic model against ceftazidime with and without AM-112, a serine beta-lactamase inhibitor.	Ceftazidime	114-125	CTX-M-1	Escherichia coli	50-57	
15155242-0	2004	High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution.	Ceftazidime	25-36	CTX-M-1	Escherichia coli	89-96	
15155242-1	2004	A clinical strain of Escherichia coli isolated from pleural liquid with high levels of resistance to cefotaxime, ceftazidime, and aztreonam harbors a novel CTX-M gene (bla(CTX-M-32)) whose amino acid sequence differs from that of CTX-M-1 by a single Asp240-Gly substitution.	Ceftazidime	113-124	CTX-M-1	Escherichia coli	230-237